Dr. Ian Flinn explains in an interview with CURE how Lunsumio VELO (mosunetuzumab) works and its impact on patients with ...
The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and only subcutaneously administered therapy for patients with epidermal growth ...
In a merger between two subcutaneous drug delivery companies, Halozyme Therapeutics is paying $750 million in cash to acquire Elektrofi. Aside from the $750 million upfront payment, the deal also ...
Merck (NYSE:MRK) said that the FDA has cleared Keytruda Qlex, a new subcutaneous version of its blockbuster cancer drug, offering a faster alternative to IV infusion, a company spokesperson confirmed ...
The FDA has approved Merck & Co.’s under-the-skin version of Keytruda, reducing treatment time burden for patients while granting the world’s bestselling drug potential blockbuster revenue protection.
Please provide your email address to receive an email when new articles are posted on . The subcutaneous pembrolizumab combination was approved for adults and ...
CAMBRIDGE, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the company has entered into a definitive agreement to acquire Massachusetts-based Alcyone Therapeutics. As ...
NEW YORK – Biogen on Thursday said it is acquiring Alcyone Therapeutics, a company developing technologies to improve delivery of antisense oligonucleotide (ASO) therapies. Under the terms of the deal ...
Trial Supports Subcutaneous Isatuximab as Effective Alternative to IV Version: Xavier Leleu, MD, PhD
The phase 3 IRAKLIA trial found that subcutaneous isatuximab delivered via an on-body system was as effective and safe as intravenous (IV) administration in relapsed/refractory multiple myeloma, ...
The LifeSite Hemodialysis System (Vasca, Inc., Tewksbury, MA, USA)is totally subcutaneous, incorporating two silicone catheters positioned in the central venous system and connected to a stainless ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results